RCEL

Avita Therapeutics Share Price - RCEL

23.64
0.57 (2.47%)
Upgrade to Real-Time
Afterhours (Closed)
23.64
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Avita Therapeutics Inc RCEL NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Low Price High Price Open Price Previous Close Last Traded
0.57 2.47% 23.64 23.00 23.67 23.15 23.07 19:00:01
Bid Price Ask Price Spread Spread % News
23.60 24.80 1.20 4.84% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume
604 53,462  23.41  1,251,669 75,629
Last Trade Time Type Quantity Stock Price Currency
16:43:05 1  23.64 USD

Avita Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 2.52B 106.67M 106.67M  5.41M  - -0.08 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - 0.00% - -

more financials information »

News Avita Therapeutics

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

RCEL Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

Avita Therapeutics Inc, formerly Avita Medical is a single product company, the RECELL system, an burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes thus avoiding or reducing the need for skin grafts. The device is approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft tissue wounds and vitiligo underway. It is currently in roll-out across the approximately 132 burn centres in the U.S. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories. It is expected to gain approval and launch in Japan via distribution partner Cosmotec shortly. In addition to its ASX listing, Avita listed on the Nasdaq in November 2019.


Your Recent History
NASDAQ
RCEL
Avita Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.